image credit- freepik
The HGP2 Rare Disease Alliance of the Asia-Pacific Region (HGP2 RaDiAnce–APAC) was officially launched in Kuala Lumpur, Malaysia on May 10.
Dr Nor Fariza Binti Ngah, Deputy Director-General of Health (Research and Technical Support) at the Ministry of Health of Malaysia, joined leading experts to discuss urgent priorities in rare disease diagnosis, genomics, and public health response.
The Alliance unites members from 10 countries to address the diagnostic gap under the framework of the Human Genome Project II (HGP2). A unified joint declaration was established for rare disease prevention and genomic medicine in Asia-Pacific. The declaration covers five key areas: ethics, accessibility, collaboration, acceleration, and public response.
The alliance, co-initiated by China's BGI Group and regional partners from across the Asia-Pacific, aims to strengthen regional collaboration in rare disease diagnosis, research in genomics, capacity building and public health response, while addressing persistent gaps in diagnostic capacity, uneven access to precision medicine, and fragmented standards and experience-sharing across the Asia-Pacific region.
As a key participant in the alliance, BGI Genomics showcased an integrated technical solution spanning precision detection, intelligent analysis, and localised talent training to deliver localised support for rare disease diagnosis across the Asia-Pacific region.
